HCW Biologics Inc. (HCWB), a clinical-stage biopharmaceutical company, announced on Monday positive developments in studies of anti-tumor drug HCW11-018b from the Big BiTE program, through a poster presented at the annual meeting of the American Association of Cancer Research (AACR).
The company developed the tetravalent, second-generation T-cell engager program Big BiTE based on the TRBC platform technology. HCW11-018b is the lead candidate of Big BiTE, designed to enhance anti-tumor activity and tolerability by cis-binding techniques toward solid tumors.
In preclinical studies, HCW11-018b showed significant shrinkage of well-established tumors, and prevented metastasis in xenograft animal models. The drug also demonstrated activation only in the tumor microenvironment, contributing to better specificity and precision.
The company plans to advance studies to treat solid tumors in pancreatic and ovarian cancers. An application for an investigational new drug (IND) is expected to be filed in the first half of 2027.
HCWB closed Monday at $0.44, up 16.88%. In the premarket shares are currently trading at $0.39, down 10.30%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.